Disc Medicine (NASDAQ:IRON) Insider Sells $526,650.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 7,500 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00. Following the sale, the insider owned 52,173 shares in the company, valued at $3,663,588.06. The trade was a 12.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Disc Medicine Price Performance

Shares of IRON traded down $0.35 during trading hours on Tuesday, reaching $70.45. The company had a trading volume of 537,249 shares, compared to its average volume of 585,545. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50. The firm has a 50 day simple moving average of $68.68 and a 200-day simple moving average of $71.50. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of -10.64 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). Research analysts expect that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IRON has been the topic of several research analyst reports. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Morgan Stanley raised their price objective on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, June 15th. Wells Fargo & Company lifted their price objective on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Wedbush reiterated an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. Finally, Truist Financial lowered their target price on Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Disc Medicine presently has a consensus rating of “Moderate Buy” and an average target price of $105.80.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently bought and sold shares of IRON. ANTIPODES PARTNERS Ltd acquired a new stake in Disc Medicine during the 4th quarter valued at $33,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Disc Medicine in the third quarter worth $38,000. KBC Group NV purchased a new stake in shares of Disc Medicine in the fourth quarter valued at $80,000. Persistent Asset Partners Ltd purchased a new stake in shares of Disc Medicine in the fourth quarter valued at $141,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Disc Medicine by 36.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock valued at $146,000 after acquiring an additional 490 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.